Adding the glycoprotein IIb/IIIa receptor antagonist tirofiban#to standard treatment for patients with unstable angina pectoris and non-Q-wave myocardial infarction (MI) can significantly reduce ischaemic complications, note researchers from the PRISM*and PRISM-plus*studies. The results of these studies were presented at the 46th Annual Scientific Sessions of the American College of Cardiology [Anaheim, US; March 1997]. Study investigator Dr Harvey White from Green Lane Hospital, Auckland, New Zealand, described the findings as a true ‘breakthrough’ in the management of this condition.